LY3549492

LY3549492 (USAN: naperiglipron) is Eli Lilly's oral non-peptide GLP-1 receptor agonist in Phase 2 for obesity and overweight. The key Phase 2 weight-management study (NCT06683508, n=288) is complete and the readout - expected during 2026 - will determine whether this becomes Lilly's second oral GLP-1 RA behind orforglipron, against a $16B+ tirzepatide franchise already in market and an increasingly crowded oral small-molecule field (Structure's aleniglipron, Viking's oral VK2735).

Novel compound - naperiglipron has not been approved anywhere. The Phase 2 weight-management trial NCT06683508 (n=288, placebo-controlled, Lilly-sponsored) is listed as COMPLETED in ClinicalTrials.gov [1]. Lilly is also running the master protocol study CWMM (NCT06143956, n=1481), which lets it slot multiple investigational obesity arms under one trial scaffold [2]. Two regional Phase 1 type 2 diabetes studies - Japanese (NCT06869018, n=92) and Chinese (NCT07073170, n=36) - are complete; a separate Phase 1 in healthy and obese/overweight participants (NCT07232732, n=120) is active and not recruiting [3]. The presence of dedicated East Asian T2D Phase 1 studies suggests Lilly intends to pursue a T2D indication alongside obesity, mirroring the tirzepatide and orforglipron development pattern, though Lilly has not publicly confirmed a T2D NDA pathway for naperiglipron. No FDA Breakthrough Therapy, Fast Track, or Priority Review designations have been disclosed for this compound. Lilly has not publicly released topline Phase 2 efficacy data as of this writing; investors should watch 2026 quarterly earnings calls and endocrinology meetings (ADA, EASD, ObesityWeek) for the readout [4]. Identifiers cross-reference cleanly: ChEMBL5944135, PubChem CID 155433819, UNII BJN78TT46S. The ChEMBL record itself is sparse (null preferred name, null max phase), which is normal for an early-Phase 2 asset where the developer hasn't pushed structural data into public databases yet. Patent protection timeline for naperiglipron is not publicly disclosed in standard databases; investors evaluating long-horizon commercial value should treat protection window as undetermined pending Lilly disclosure or USPTO filings keyed to the specific composition-of-matter claim.

GLP-1 is a gut hormone released after you eat. It tells the pancreas to put out insulin, tells the brain you're full, and slows stomach emptying so meals stay with you longer [5]. Drugs that mimic GLP-1 - semaglutide (Wegovy/Ozempic), tirzepatide (Zepbound/Mounjaro, which hits both GLP-1 and GIP receptors) - exploit all three effects to lower blood sugar and drop weight. Naperiglipron is a non-peptide small molecule, meaning you can swallow it as a pill instead of injecting a peptide. The chemistry sits in the GLP-1 receptor's binding pocket and flips the same molecular switch the natural hormone flips, just with a different key - same downstream 'you're full, release insulin' signal inside the cell [5]. Target validation is about as strong as it gets in metabolic disease: five approved peptide GLP-1 RAs, one approved dual agonist, and Lilly's own orforglipron Phase 3 ATTAIN-1 readout (August 2025) showing the oral non-peptide approach works [9]. The unsettled questions are mechanical, not biological. Can a small molecule match injectable peptides on weight loss (peptides hit 15-22% body-weight reduction, orforglipron Phase 3 hit up to ~12% at 72 weeks [9], Structure's aleniglipron hit up to 16% in Phase 2 at 36 weeks [10])? Can it avoid the liver-injury risk that took down Pfizer's danuglipron in April 2025 after a single drug-induced liver injury in a dose-optimization study [6]? Can patients tolerate the GI side effects when titration is daily-oral rather than weekly-subcutaneous?

NCT06683508 is a Phase 2 randomized, placebo-controlled study in adults with obesity (BMI ≥30) or overweight (BMI ≥27 with weight-related comorbidity), n=288, primary endpoint percent change from baseline in body weight [1]. That's the standard obesity Phase 2 endpoint - same metric Wegovy and Zepbound were judged on. Comparator is placebo; no active control. The master protocol CWMM (NCT06143956, n=1481) is the umbrella infrastructure that lets Lilly plug investigational obesity arms in and out efficiently, but it doesn't tell us anything specific about naperiglipron beyond Lilly's organizational seriousness about the asset [2]. Concerns are minor. 288 patients is adequate for go/no-go decision-making and dose-finding but light if Lilly wants to power for tolerability subgroups. There's no head-to-head against orforglipron, so the comparison investors actually care about - naperiglipron vs Lilly's other oral GLP-1 RA - will be cross-trial and noisy. Trial duration isn't fully specified in the public registry summary; typical Phase 2 obesity studies run 24-36 weeks to capture the weight-loss plateau, which matters because the orforglipron Phase 3 benchmark is 72 weeks - investors should weight-loss-adjust naperiglipron's shorter-duration topline before comparing. The Phase 1 program (NCT07232732, NCT06869018, NCT07073170) is properly thorough - separate East Asian populations, T2D and obesity, healthy volunteers - which de-risks pharmacokinetic (PK) variability across ethnic populations and supports the diabetic indication path. Naperiglipron's dosing schedule (once vs twice daily, fasting requirement à la orforglipron) has not been disclosed publicly.

Our model estimates this drug has an 18% chance of eventually reaching approval. That starting point comes from the historical approval rate for Phase 2 drugs in this area, which is about 35%. The estimate is pulled down from there mainly because earlier-phase results were weak or limited, and the trial uses a randomized design. It is partly offset by larger-than-typical enrollment and the sponsor's strong track record, but not enough to lift it back to the baseline.

Efficacy risk is the headline. Oral non-peptide GLP-1 RAs are now clustering in the 11-16% weight-loss range - Structure's aleniglipron hit up to 16% in Phase 2 ACCESS II at 36 weeks [10], Viking's oral VK2735 hit up to 12.2% at 13 weeks in VENTURE-Oral [11], orforglipron landed at ~12% in Phase 3 at 72 weeks [9] - versus injectable peptides at 15-22%. If naperiglipron doesn't materially beat orforglipron and stay competitive with aleniglipron, Lilly has no commercial reason to develop both internally - naperiglipron becomes a backup or gets shelved. Safety: on-target GI tox (nausea, vomiting, diarrhea) is the dominant tolerability problem across the entire class - aleniglipron's Phase 2 reported 65% nausea, 32% vomiting, 11% AE-driven discontinuation [10]; orforglipron Phase 3 reported 21.9-24.4% overall discontinuation across doses [9]. Off-target concerns specific to oral small molecules include hepatotoxicity - Pfizer terminated danuglipron in April 2025 after a single drug-induced liver injury in one patient during a dose-optimization study (not December 2023, and not from a Phase 1 signal - the December 2023 event was Pfizer dropping the twice-daily formulation for GI tolerability) [6] - and cardiac signals from off-target ion channel binding, which any new small molecule has to clear. Execution risk: Lilly is running multiple obesity assets concurrently - orforglipron in Phase 3, retatrutide (GLP-1/GIP/glucagon triple agonist) in late-stage development, tirzepatide line extensions - and naperiglipron has to compete internally for capital and trial slots. Competitive risk: external oral programs at Structure (aleniglipron, advancing to Phase 3 mid-2026 [10]) and Viking (VK2735 oral, Phase 3 planned later 2026 [11]) could reach market first or with better efficacy, eroding the strategic case for Lilly to field two internal oral GLP-1s. Commercial risk is real even if approved. Pharmacy benefit manager (PBM) - the middlemen who negotiate drug coverage - gatekeeping of GLP-1 RAs has tightened with prior authorization, step therapy, and outright exclusions. The oral market may consolidate around one or two products. Cannibalization is the killer - naperiglipron's sales come directly out of orforglipron's pocket unless it's clearly differentiated on efficacy, tolerability, or dosing schedule.

Watch, not signal. Phase 2 readout from NCT06683508 is the next event that actually moves this name - until topline drops, we're inferring from chemistry and Lilly's track record. The specific data point that matters: top-dose percent weight loss at 24 or 36 weeks, ideally paired with GI discontinuation rate and any liver function test (LFT) signal. Land above orforglipron's ~12% (and preferably closing on aleniglipron's 16%) with GI-driven discontinuation materially below orforglipron's ATTAIN-1 actuals - overall 21.9-24.4%, AE-driven 5.1-10.3% [9] - and Lilly has a real second oral GLP-1 RA worth pushing to Phase 3. Note this comparison is imperfect: naperiglipron Phase 2 will report at 24-36 weeks vs ATTAIN-1's 72-week endpoint, so weight loss should be discounted modestly and discontinuation rates should be expected to look better at the shorter timepoint. Land at or below orforglipron with similar tolerability and naperiglipron likely gets repositioned (combination, lower-dose maintenance) or quietly killed. Lilly's obesity franchise drove most of the company's growth in 2024 - tirzepatide as Mounjaro for T2D and Zepbound for weight loss were the single biggest growth driver for what was a $45B-revenue company in 2024, with 2025 guidance projecting ~$58-61B [8]. The strategic question for Lilly isn't whether oral GLP-1 RAs work (orforglipron answered that [9]) but how many oral shots on goal makes sense before they cannibalize each other - especially with Structure and Viking advancing competing oral programs into Phase 3 over the next year [10][11]. Check back at Lilly's Q3 or Q4 2026 earnings calls, or any 2026 endocrinology meeting, for the readout. If Lilly stays silent on naperiglipron through end of 2026 while orforglipron coverage dominates the obesity discussion, that's its own signal - Lilly broadcasts wins fast and buries losers in pipeline tables.